知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.029 秒)

    Therapeutic Macrolide Compounds and Their Use
    1.
    发明申请
    Therapeutic Macrolide Compounds and Their Use 审中-公开
    治疗性大环内酯类化合物及其用途

    公开(公告)号：US20110237566A1

    公开(公告)日：2011-09-29

    申请号：US13130144

    申请日：2009-11-24

    申请人： Rustum S. Boyce ,  Muhammad Sofian Asi Sihombing ,  Hiroki Sone

    发明人： Rustum S. Boyce ,  Muhammad Sofian Asi Sihombing ,  Hiroki Sone

    IPC分类号： A61K31/553 ,  C07D313/00 ,  C07D413/14 ,  C07D405/14 ,  C07D267/10 ,  C07D243/08 ,  A61K31/336 ,  A61K31/5355 ,  A61K31/497 ,  A61K31/4523 ,  A61K31/551 ,  A61P35/00

    CPC分类号： C07D407/06 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14

    摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.

    摘要翻译： 本发明一般涉及治疗化合物的领域，更具体地涉及某些大环内酯类化合物（为方便起见，本文统称为“MC化合物”），其尤其可用于治疗癌症。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以治疗增殖性疾病如癌症，以及治疗由调节介导的疾病和病症 （例如抑制）细胞增殖，任选与另一种试剂组合。

    Lipopeptide compounds and their use
    2.
    发明授权
    Lipopeptide compounds and their use 有权
    脂肽化合物及其用途

    公开(公告)号：US08921309B2

    公开(公告)日：2014-12-30

    申请号：US13128661

    申请日：2009-11-24

    申请人： Rustum S. Boyce ,  Joseph Cherian ,  Cleofe Calanasan ,  Muhammad Sofian Asi Sihombing

    发明人： Rustum S. Boyce ,  Joseph Cherian ,  Cleofe Calanasan ,  Muhammad Sofian Asi Sihombing

    IPC分类号： C07K7/56 ,  C07K7/54 ,  C07K7/52 ,  C07K7/50 ,  A61K38/12 ,  A61K38/04 ,  A61K38/00 ,  A01N37/18

    CPC分类号： C07K7/56 ,  A61K38/00

    摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.

    摘要翻译： 本发明一般涉及治疗化合物领域，更具体地涉及包含带有脂质侧链的环状肽（为方便起见，统称为“LP化合物”）的某些脂肽化合物，其特别是抗微生物剂 ，特别是抗菌。 本发明还涉及包含这种化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以提供抗微生物功能，特别是抗菌功能，以及用于治疗介导的疾病和病症 特别是通过抗微生物功能改善的微生物，特别是细菌，特别是抗菌功能，包括细菌疾病，任选地与另一种试剂，例如另一种抗菌剂组合。

    Lipopeptide Compounds and Their Use
    3.
    发明申请
    Lipopeptide Compounds and Their Use 有权
    脂肽化合物及其用途

    公开(公告)号：US20110224129A1

    公开(公告)日：2011-09-15

    申请号：US13128661

    申请日：2009-11-24

    申请人： Rustum S. Boyce ,  Joseph Cherian ,  Cleofe Calanasan ,  Muhammad Sofian Asi Sihombing

    发明人： Rustum S. Boyce ,  Joseph Cherian ,  Cleofe Calanasan ,  Muhammad Sofian Asi Sihombing

    IPC分类号： A61K38/12 ,  C07K7/60 ,  A61P31/04

    CPC分类号： C07K7/56 ,  A61K38/00

    摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.

    摘要翻译： 本发明一般涉及治疗化合物领域，更具体地涉及包含带有脂质侧链的环状肽（为方便起见，统称为“LP化合物”）的某些脂肽化合物，其特别是抗微生物剂 ，特别是抗菌。 本发明还涉及包含这种化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以提供抗微生物功能，特别是抗菌功能，以及用于治疗介导的疾病和病症 特别是通过抗微生物功能改善的微生物，特别是细菌，特别是抗菌功能，包括细菌疾病，任选地与另一种试剂，例如另一种抗菌剂组合。

    Guanidino compounds
    8.
    发明授权
    Guanidino compounds 失效
    胍基化合物

    公开(公告)号：US06716840B2

    公开(公告)日：2004-04-06

    申请号：US10118730

    申请日：2002-04-08

    申请人： Daniel Chu ,  Rustum S. Boyce ,  David Duhl ,  Bryan H. Chang

    发明人： Daniel Chu ,  Rustum S. Boyce ,  David Duhl ,  Bryan H. Chang

    IPC分类号： A61K315375

    CPC分类号： C07D209/46 ,  C07D209/48 ,  C07D217/24 ,  C07D235/08 ,  C07D235/10

    摘要： Compounds having the general structure I are provided: X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of and L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r”) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.

    摘要翻译： 提供具有通式结构I的化合物：X和Y独立地选自CH 2，N，NR 9，C = O，C = S，S = O，SO 2，S，O， （R 6 R 7）n，C（= O） - （CR 6 R 7）n和C（= S） - （CR 6 R 7）n，其中n为1 W选自N，O，S，S = O，SO 2，C（O），NC（O），NC（S），OC （O），OC（S），C（NR 10），C（NOR 10））和共价键。 Z 1，Z 2和Z 3独立地选自取代的碳和氮。 式I化合物是黑皮质素-4受体（“MC-4r”）的激动剂，因此可能具有控制人类MC-4r作用相关疾病如肥胖和II型糖尿病的有用性质。